Critical Therapeutics, Inc. 2006 Executive Bonus Goals Approval

Summary

Critical Therapeutics, Inc.'s Board of Directors approved specific company goals for 2006, which will be used to determine executive officer bonuses for that fiscal year. The goals focus on increasing sales and regulatory progress for the drug zileuton, advancing research and development for other products, maintaining financial stability through cash management and capital raising, and recruiting and retaining key employees. These objectives are intended to guide company performance and executive compensation decisions for 2006.

EX-10.51 8 b58508ctexv10w51.txt EX-10.51 CRITICAL THERAPEUTICS, INC. 2006 COMPANY GOALS EXHIBIT 10.51 CRITICAL THERAPEUTICS, INC. 2006 COMPANY GOALS On November 30, 2005, based on the recommendation of the Compensation Committee of the Board of Directors of Critical Therapeutics, Inc., our Board of Directors approved company goals for 2006. These company goals will be considered in determining bonus amounts for our executive officers in respect of our 2006 fiscal year. The company goals for 2006 include: - enhancing the commercial value of zileuton by meeting ZYFLO(R) sales targets, making specified regulatory filings and achieving specified business development goals; - progressing our research and development pipeline by making specified regulatory filings and achieving specified pre-clinical and clinical development milestones and business development goals for our other product candidates; - maintaining our financial position by managing our cash balance and raising capital, as necessary, to support our operating plan and communicating effectively with investors; and - recruiting and retaining key employees to create an effective organization.